Investigation of platelet function in patients with chronic kidney disease stages IV‐V

Abstract

The mean global prevalence of chronic kidney disease (CKD) stages III-V is 10.6% (95% CI: 9.2-12%-2%), based on a meta-analysis of observational studies. 1 Furthermore, this will rise due to an ageing world population and an increase in the prevalence of predisposing conditions, such as diabetes mellitus. CKD affects haemostasis in a complex fashion, where both pro-thrombotic and bleeding diatheses are observed. 2,3 There is an increased prevalence and incidence of cardiovascular disease and related mortality in patients with CKD,